Investors Alert: Novo Nordisk A/S Lawsuit Details
NEW YORK – Recently, Bernstein Liebhard LLP, a notable firm focusing on investor rights, has issued a reminder to all shareholders of Novo Nordisk A/S regarding an impending deadline related to a securities fraud class action lawsuit initiated against the company.
Is Joining the Class Action Right for You?
Many investors may wonder whether they should participate in this class action lawsuit. Here are some primary questions to consider:
1. Have You Invested in Novo Nordisk A/S?
If you hold shares of Novo Nordisk A/S, which trades under the ticker NVO, you may have a stake in this legal action.
2. When Did You Purchase Shares?
It’s crucial to determine if your shares were purchased within the time period of May 7, 2025, to July 28, 2025, as this timeframe marks the relevant period for this lawsuit.
3. Have You Suffered Financial Loss?
If you experienced a loss in your investment due to the allegations against Novo Nordisk A/S, you may want to explore your legal options.
Details of the Lawsuit
A lawsuit has been filed in the United States District Court for the District of New Jersey, representing a class of investors who purchased or acquired Novo securities within the specified time frame. The lawsuit alleges breaches of the Securities Exchange Act of 1934, specifically alleging that the company and certain senior executives made misleading statements regarding Novo's growth potential stemming from its diabetes and obesity medication, GLP-1.
Taking Action: Deadlines and Responsibilities
If you wish to take on the role of a lead plaintiff for the class, you are required to file your papers by the specified deadline, September 30, 2025. A lead plaintiff acts on behalf of all class members in directing the lawsuit, but it is important to note that sharing in any possible recovery does not necessitate serving as a lead plaintiff. If you opt not to take any action, you will still retain your status as an absent class member.
Legal Representation and Costs
All legal representation for this lawsuit will be undertaken on a contingency fee basis. Shareholders will not incur any fees or expenses unless there is a successful recovery.
About Bernstein Liebhard LLP
Since 1993, Bernstein Liebhard LLP has successfully recovered over $3.5 billion for its clients. Not only does the firm advocate for individual investors, but it has also represented some of the country's largest public and private pension funds, diligently monitoring assets and pursuing litigation when necessary. Their consistent success in litigating class actions has earned the firm recognition on The National Law Journal's "Plaintiffs' Hot List" multiple times.
Contact for More Information
If you are a shareholder seeking further information or wish to discuss your situation about this lawsuit, please reach out to:
Peter Allocco
Investor Relations Manager
Bernstein Liebhard LLP
(212) 951-2030
pallocco@bernlieb.com
Frequently Asked Questions
What is the nature of the lawsuit against Novo Nordisk A/S?
The lawsuit alleges securities fraud related to misleading statements about the company’s growth potential from its diabetes treatment.
What should I do if I owned shares of Novo Nordisk during the specified period?
You may want to participate in the class action lawsuit or seek legal options to recover any losses incurred.
What is the deadline for filing as a lead plaintiff?
Those wishing to file as a lead plaintiff must do so by September 30, 2025.
Are there any costs involved in joining the lawsuit?
No, representation is on a contingency fee basis; investors do not pay fees unless there is a successful recovery.
How can I contact Bernstein Liebhard LLP for legal guidance?
You can contact Peter Allocco through the provided phone number or email address for more information.
